Has significantly reduced side effects of the current diabetes drugs on the market
Maximize effectiveness by reducing drug and insulin resistance from long-term use
 |
SEOUL, South Korea, May 7, 2021 /PRNewswire/ — Nexturn Bio Inc., a subsidiary of Nexturn Bioscience Co., Ltd. (KOSDAQ:89140), said it has secured a 50% stake in RosVivo Therapeutics Inc., a U.S. new drug developer, as its first investment destination. RosVivo recently developed RSVI-301, a new drug pipeline that utilizes miRNA (MicroRNA), which is expected to be the next-generation drug, following mRNA (Messenger RNA), which has attracted attention as a Covid-19 vaccine. Unlike rare diseases or cancer, targeting chronic disease “diabetes,” seems to have positively affected Nexturn Bio’s investment.
According to data released by the WHO in April this year, the number of diabetes patients worldwide is about 420 million, which has maintained a high prevalence rate until recently. The figure of the patients proves that diabetes drugs currently developed up to the fourth generation are not as effective as expected. In fact, Liraglutide, which are known to be the most effective component of diabetes drugs ever approved by the FDA, have also reported vomiting, diarrhea, constipation and indigestion as side effects from the clinical stages. The side effect reduction of RSVI-301 is more noticeable in the table below, compiled according to the research paper provided by RosVivo. (figure 1).
Rosvivo’s new miRNA treatment RSV1-301 vs. diabetes drug on the market
Furthermore, it has been observed that RSVI-301 reduces insulin resistance by normal levels during repeated drug infusions (figure 2). With the result of being completely opposite to the existing diabetes drugs, the possibility of overcoming insulin resistance raises RSVI-301 expectations in the related industry. The low side effects and the long-term lasting effects of RSVI-301 are expected to play a major competitive role in the future diabetes market in regard to patient convenience. An official from Nexturn Bio Inc. added, “We will continue to provide generous support for RosVivo’s development of new drugs as well as to cure diabetes together.”
Insulin resistance and secretion changes after injection of the new drug miRNA
Support Independent Community Journalism
Dear Reader,The Indian Sun exists for one reason: to tell stories that might otherwise go unheard.
We report on local councils, state politics, small businesses and cultural festivals. We focus on the Indian diaspora and the wider multicultural community with care, balance and accountability. We publish in print and online, send regular newsletters and produce video content. We also run media training programs to help community organisations share their own stories.
We operate independently.
Community journalism does not have the backing of large media corporations. Advertising revenue fluctuates. Platform algorithms change. Costs continue to rise. Yet the need for credible, grounded reporting in a multicultural Australia has never been greater.
When you support The Indian Sun, you support:
• Independent reporting on issues affecting migrant communities
• Coverage of local and state decisions that shape daily life
• A platform for small businesses and community groups
• Media training that builds skills within the community
• Journalism accountable to readers
We cannot cover everything, but we work to cover what matters.
If you value thoughtful reporting that reflects Australia’s diversity, we invite you to contribute. Every donation helps us maintain the quality and consistency of our work.
Please consider making a contribution today.
Thank you for your support.
The Indian Sun Team
